|
|
Imperial College London
Level 2, Bessemer Building, London SW7 2AZ United Kingdom
phone:+44 (0) 20 7594 1326
fax:
|
|
| Symbol |
Private |
| Founded |
2006 |
| Employees |
5 |
|
|
| www.repregen.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| RepRegen is a medical device company that develops products to repair and regenerate tissue in vivo |
|
| Management |
| Stephen Rietiker, MD, Chairman; Ian Brown, MBA, Chief Executive Officer |
| |
|
|
| |
|
| Keywords |
| repair, regeneration, technology, mend, regrow, hard, tissue, bone, soft, tissue, cartilage, orthopaedic, trauma, spine, craniomaxillofacial, biomaterials, regeneration, bioactive, ceramics, biomimetic, fibrous, polymer, scaffolds, Strontium, bioceramics, bone repair |
|
|
|
| Description |
|
RepRegen is an emerging medical device company using patent-pending repair and
regeneration technology in two platforms designed to mend and re-grow tissue in
vivo. The first platform is focused on bone and other (hard) tissue, whereas the second
platform is focused on muscle and other (soft) tissue. RepRegens lead product is
StronBone bone graft substitute bioactive glass with Strontium for hard tissue repair
indicated for orthopedic and craniomaxillofacial applications. All of RepRegen�s
products use proprietary smart biomaterials and scaffolds which compromise major
innovations in bioactive ceramics and bio-mimetic polymers technology, such as the use
of strontium which boots the formation of bone tissue for faster and more efficient repair.
A spin-out company from Imperial College London, RepRegen is headquartered within
the Imperial College Incubator. |
|
| Technology / Differentiation |
| RepRegen is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in vivo. The first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue.
Hard Tissue Platforms
The Hard Tissue platform is a family of modified bioactive ceramics used to repair and regenerate bone in surgical fields such as orthopaedic, cranio maxillo facial, periodontal and dental. The first product from the platform is StronBone. As a result of the incorporation of carefully controlled amounts of strontium and other ions, into the bioactive ceramic, StronBone is a Bone Graft Substitute that offers outstanding performance.
Strontium has a long record of safe and effective use in medicine. Strontium is found in our bodies and in our diets, it is naturally absorbed by our bodies, and it has a long history of being used in health supplements or toothpastes to strengthen bones and teeth. StronBones superior performance constitutes a significant competitive advantage over existing products in the market and over products known to be currently under development. StronBone is ready for product launch in Europe now.
Note: In the EU, StronBone Bone Graft Substitute is a medical device which has CE Marking approval. In the USA, StronBone Bone Graft Substitute is a medical device product which has not yet been cleared by the FDA and can therefore only be used for investigational use.
Soft Tissue Platform
The Soft Tissue platform is a family of synthetic extracellular matrices aimed at repairing and regenerating soft tissue such as cartilage, tendon and ligament in surgical fields such as musculoskeletal and sports medicine. The first product from the Soft Tissue platform will most likely be focused on cartilage repair and regeneration.
The ability to control topography and chemistry of synthetic extracellular matrices provides exciting potential for stimulating repair and regeneration of almost any tissue type as part of the matrices biodegradation. All tissues are hierarchically organised down to the nanoscale and comprise nanoscaled extracellular matrix (ECM) fibres. Prof Molly Stevens, RepRegen Chief Scientific Officer and leading Imperial College London scientist, highlighted in her recent Science paper (2005) that while conventional scaffolds for tissue engineering have been designed with a microporous structure, it is likely that cells require the full context of a three-dimensional nanofibrous matrix to maintain their phenotypic shape and establish natural behaviour patterns.
RepRegen is pursuing an improved biomimetic approach to biomaterials design that involves the engineering of preferentially aligned fibres. Our aim is to produce electrospun preferentially aligned fibres that are continuous, and allow for integrated manufacturing of 3D fibre matrices as tissue scaffolds with high porosity, high spatial interconnectivity and controlled alignment of fibres to direct cell orientation and migration.
These synthetic extracellular matrices offer exciting possibilities for medical devices in the form of 3D fibre matrices as tissue scaffolds implanted with or without stem cells, growth factors or other biologics to stimulate repair and regeneration of almost any tissue type. Future proof-of-concept targets potentially include repair and regeneration in cardiac applications, pancreas (diabetes), spinal cord injury, bladder degeneration and more. |
|
| Market / Customers |
The worldwide market for the orthopaedic biomaterials sector is expected to soar to $8.8 billion by 2012. But of keen interest to RepRegen is not only that this sector is enormous and growing rapidly but also that it is extremely fragmented. Consequently, RepRegen expects to have numerous sales and out-licensing opportunities.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members